Status:
TERMINATED
Switch of Renin-Angiotensin System Inhibitors in Patients With Covid-19
Lead Sponsor:
University of Sao Paulo
Conditions:
Covid19
Angiotensin II Receptor Antagonist Adverse Reaction
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
PHASE3
Brief Summary
The SWITCH-COVID trial will randomize patients with COVID-19 that are currently using renin-angiotensin system inhibitors for treating hypertension to maintain the therapy during in-hospital stay or s...
Detailed Description
Patients eligible for the study, after signing informed consent will be randomized 1:1 for maintenance of renin-angiotensin system inhibitors or switching the antihypertensive therapy for other classe...
Eligibility Criteria
Inclusion
- Hypertension in use of renin-angiotensin system inhibitors
- Confirmed COVID-19 infection by rt-PCR, serology tests or typical clinical presentation and chest CT.
- Symptoms onset \< 96h
- Need for hospitalization
Exclusion
- Heart failure
- Previous cerebrovascular disease
- Previous myocardial infarction
- Blood pressure \> 180 x 100 mmHg
- Need for 3 or more anti-hypertensive classes
- Use os spironolactone
- Severe pulmonary disease
- Contraindication for using other anti-hypertensive classes (calcium channel blockers, hydralazine, diuretics or nitrates)
Key Trial Info
Start Date :
July 25 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 28 2021
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT04493359
Start Date
July 25 2020
End Date
September 28 2021
Last Update
October 6 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto do Coração - Incor HCFMUSP
São Paulo, São Paulo, Brazil, 05403-900